These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 18790197)

  • 1. Rituximab in highly sensitized kidney transplant recipients.
    Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
    Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of high-dose human immune globulin in highly sensitized patients on the kidney transplant waiting list: one center's experience.
    Gozdowska J; Urbanowicz A; Perkowska-Ptasinska A; Michalska K; Chmura A; Szmidt J; Durlik M
    Transplant Proc; 2009 Oct; 41(8):2997-3001. PubMed ID: 19857660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.
    González E; Gutiérrez E; Hernández Y; Roselló G; Gutiérrez MJ; Martínez EG; Manzanera MJ; García JA; Praga M; Morales JM; Andrés A
    Transplant Proc; 2005 Nov; 37(9):3736-7. PubMed ID: 16386522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney transplantation across a positive crossmatch: a single-center experience.
    Santos C; Costa R; Malheiro J; Pedroso S; Almeida M; Martins LS; Dias L; Tafulo S; Henriques AC; Cabrita A
    Transplant Proc; 2014; 46(6):1705-9. PubMed ID: 25131017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
    Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
    Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.
    Kute VB; Vanikar AV; Trivedi HL; Shah PR; Goplani KR; Patel HV; Gumber MR; Patel RD; Kanodia KV; Suthar KS; Trivedi VB; Modi PR
    Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):662-9. PubMed ID: 21743208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
    Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
    Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
    Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
    N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and late humoral rejection: a clinicopathologic entity in two times.
    Péfaur J; Díaz P; Panace R; Salinas P; Fiabane A; Quinteros N; Chea R; Naranjo E; Wurgaft A; Beltran E; Elgueta S; Wegmann ME; Gajardo JG; Contreras L
    Transplant Proc; 2008 Nov; 40(9):3229-36. PubMed ID: 19010241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.
    Naderi GH; Mehraban D; Ganji MR; Jafarpouriani M; Latif AH
    Transplant Proc; 2009 Sep; 41(7):2768-71. PubMed ID: 19765430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft].
    Rufino Hernández JM; Cabello Moya E; González-Posada JM; Hernández Marrero D; Pérez Tamajón L; Marrero Miranda D; García Rebollo S; Martín Urcuyo B; Rodríguez Hernández A; Franco Maside A; Barrios del Pino Y; Rodríguez Rodríguez R; Maceira Cruz B; Torres Ramírez A; Salido Ruiz E
    Nefrologia; 2010; 30(2):252-7. PubMed ID: 20098463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.
    Tan J; Yang S; Wu W
    Transplant Proc; 2005 Mar; 37(2):903-5. PubMed ID: 15848570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.